Sionna Therapeutics completes Phase 1 dosing for NBD1 stabilizers SION-719 and SION-451, with Phase 2a trials set for 2025. Sionna Therapeutics announced the completion of Phase 1 dosing for its NBD1 ...
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination ...
Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets WALTHAM, Mass., Oct. 24, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results